Limited Use Note(s) |
|
RALOXIFENE HCL60mg Tab
| Reason For Use Code | Clinical Criteria |
|---|---|
| For the treatment of osteoporosis in postmenopausal women who have: | |
| 373 | Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate. |
| Failure is defined as: continued loss of bone mineral density (loss of more than 3%) after two years of therapy; or a new osteoporosis related fracture after one year of therapy. | |
| LU Authorization Period: Indefinite. |